Michael Hudecek, MD: “Can Cancer Be Cured with a Bag of T Cells? Novel Targets and Technologies for CAR T”
Thursday, May 3, 2018, 10 am, Hygiene Institute, Lecture Hall 2, Kinderspitalgasse 15, Vienna IX
COLLOQUIUM IN PATHOPHYSIOLOGY, INFECTIOLOGY AND IMMUNOLOGY
Dr. Michael Hudecek studied medicine at Leipzig University, where he focused his doctoral thesis work under the supervision of Dietger Niederwieser on the role of the minor histocompatibility antigen HA1 in graft versus leukemia reaction. For his postdoctoral studies he joined the laboratory of Stanley Riddell at the Fred Hutchinson Cancer Research Center in Seattle, USA, where he engineered tumor-reactive Chimeric Antigen Receptor (CAR) T cells for adoptive immunotherapy. He returned in 2012 to Germany as a resident physician to start his own laboratory at the Julius Maximilians University Medical School in Würzburg.
Dr. Hudecek’s research interest encompass (1) the identification of tumor-associated antigens, (2) the engineering of tumor-specific CAR T cells and (3) adoptive immunotherapy with the use of CAR-T cells, tumor-specific T cells and antibodies. He is a member of the Bavarian Academy of Sciences and a recipient of the m4-award of the Free State of Bavaria and Artur-Pappenheim Award of the German Society for Hematology and Medical Oncology.
- Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Meijide JB, Bonig H, Herr W, Sierra J, Einsele H, Hudecek M (2018) CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia doi: 10.1038/s41375-018-0009-0. [Epub ahead of print] PMID: 29472720
- Gogishvili T, Danhof S, Prommersberger S, Rydzek J, Schreder M, Brede C, Einsele H, Hudecek M (2017) SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. Blood 130(26):2838-2847. doi: 10.1182/blood-2017-04-778423. Epub 2017 Oct 31. PMID: 29089311
- García-Guerrero E, Gogishvili T, Danhof S, Schreder M, Pallaud C, Pérez-Simón JA, Einsele H, Hudecek M (2017) Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab Blood 129(25):3386-3388. doi: 10.1182/blood- 2017-03-770776 PMID: 28476749
- Monjezi R, Miskey C, Gogishvili T, Schleef M, Schmeer M, Einsele H, Ivics Z, Hudecek M (2016). Enhanced Engineering of Chimeric Antigen Receptor (CAR)-Modified T Cells at Genomic Safe Harbor Loci Using Non-Viral Sleeping Beauty-Mediated Transposition From Minicircle Vectors. Leukemia doi: 10.1038/leu.2016.180.
Host: Johannes Huppa
zurück zu: CePII